

**THE UNITED STATES PATENT AND TRADEMARK OFFICE  
POST APPLICATION DIVISION**

Serial No.: 87/931,649

Mark: TRICIDA

Filing Date: May 22, 2018

Applicant: Tricida, Inc.

**DECLARATION OF KATHERINE A. KEATING  
IN SUPPORT OF PETITION TO THE DIRECTOR FOR POST-ALLOWANCE  
AMENDMENT OF GOODS DESCRIPTION  
PURSUANT TO 37 C.F.R. §§ 2.146 AND TMEP § 1107**

I, Katherine Keating, declare that:

1. I am an attorney at Bryan Cave Leighton Paisner LLP, counsel for applicant Tricida, Inc. (“Applicant”) and attorney of record for the above-referenced application (the “Application”). I make this declaration in support of Applicant’s petition to the director, pursuant to 37 CFR §§ 2.146 and TMEP § 1107, to amend the description of goods following issuance of a Notice of Allowance for the Application. I can testify competently and of my own personal knowledge to the matters set forth herein.

2. Applicant is the owner of record of Serial No. 87/931,649 for the mark TRICIDA.

3. Applicant filed the Application on May 22, 2018.

4. On December 28, 2018, a Notice of Allowance was issued for the Application.

5. The goods currently identified in the Application are:

pharmaceutical preparations for the treatment of metabolic acidosis associated with chronic kidney disease; pharmaceutical preparations for the treatment of renal diseases and disorders; pharmaceutical preparations for increasing bicarbonate levels; non-absorbed pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of metabolic acidosis and renal disorders; polymeric pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of metabolic acidosis and renal disorders (class 5).

6. Applicant has entered into an agreement with a third party pursuant to which it has agreed to limit the goods identified in the Application by clarifying that the TRICIDA mark functions as a house mark for those goods.

7. Accordingly, Applicant seeks to amend the goods identified in the Application as follows:

**A house mark for** pharmaceutical preparations for the treatment of metabolic acidosis associated with chronic kidney disease; **a house mark for** pharmaceutical preparations for the treatment of renal diseases and disorders; **a house mark for** pharmaceutical preparations for increasing bicarbonate levels; **a house mark for** non-absorbed pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of metabolic acidosis and renal disorders; **a house mark for** polymeric pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of metabolic acidosis and renal disorders.

8. The requested amendment to the goods identification in the Application would not broaden the scope of goods covered by the Application and would not require re-publication of the Application.

Being hereby warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements and the like may jeopardize the validity of this document, I declare that all statements made of my own knowledge are true; and that all statements made on information and belief are believed to be true.

Dated: April 15, 2020

/katherine keating/  
Katherine Keating  
Bryan Cave Leighton Paisner LLP